ConCallIQ
Go Pro
Home › Sunpharma › PAT History

Sunpharma PAT History — Quarter by Quarter

Sunpharma's pat moved from ₹2,006 Cr in Q1 FY24 to ₹3,369 Cr in Q3 FY26, a 67.9% change over 11 quarters. The table keeps each quarter linked back to the underlying earnings page.

PAT by Quarter

QuarterPAT (₹ Cr)YoY Change
Q3 FY26₹3,369 Cr+16%
Q2 FY26₹3,118 Cr+2.6%
Q1 FY26₹2,279 Cr-19.6%
Q4 FY25₹2,154 Cr—
Q3 FY25₹2,913 Cr+15%
Q2 FY25₹3,040 Cr+28%
Q1 FY25₹2,861 Cr+40.2%
Q4 FY24₹2,659 Cr+33.8%
Q3 FY24₹2,561 Cr+16.5%
Q2 FY24₹2,385 Cr+5%
Q1 FY24₹2,006 Cr—

What management said about pat

G

Q3 FY26 · Semaglutide launch in India on patent expiry

Sun Pharma plans to launch generic semaglutide in India on day one of patent expiry for both chronic weight management and type 2 diabetes, under brands NovelTreat and SemaTrinity.

G

Q3 FY25 · Leqselvi launch timeline dependent on litigation outcome

Oral arguments for Leqselvi patent litigation expected in April 2025; if favorable, launch could occur before patent expiry in December 2026.

G

Q2 FY25 · Leqselvi launch readiness within weeks of favorable judgment

Management stated they would be ready to launch Leqselvi within a couple of weeks post a favorable court ruling on the patent litigation.

G

Q2 FY24 · Tax rate to inch up on annual basis

Tax rate expected to be higher than last year's 8.8% due to profit mix across jurisdictions.